Showing 1951-1960 of 5842 results for "".
- FDA Approves Otezla for Pediatric Psoriasishttps://practicaldermatology.com/news/fda-approves-otezla-for-pediatric-psoriasis-treatment/2468356/Amgen’s Otezla® (apremilast) has been approved by the U.S. Food and Drug Administration (FDA) for pediatric use in treating moderate to severe plaque psoriasis, making it the first oral option for this condition in children. The approval, which to patients ages 6 and older who weigh at lea
- Survey: Majority of Physicians Report Feelings of Burnouthttps://practicaldermatology.com/news/survey-majority-physicians-report-feelings-burnout/2468314/A majority of physicians reported feelings of burnout in 2024, according to a new survey. Researchers for the 2024 Survey of America's Current and Future Physicians, which focuses on the state of physician, resident, and medical student wellbeing, included 1,723 responses and co
- DELTA FORCE: Delgocitinib Cream Superior for Chronic Hand Eczema Treatmenthttps://practicaldermatology.com/news/delta-force-delgocitinib-cream-superior-chronic-hand-eczema-treatment/2468306/New data from the DELTA FORCE trial presented at the 33rd European Academy of Dermatology and Venereology (EADV) Congress suggests that delgocitinib cream showed superior efficacy and safety compared to oral alitretinoin for the treatment of chronic hand eczema (CHE). “The completion of th
- SEEN Hair Care Closes $9 Million in Series A Fundinghttps://practicaldermatology.com/news/seen-hair-care-closes-9-million-series-funding/2468305/SEEN, the award-winning haircare brand developed by dermatologist Iris Rubin, MD, has closed a $9 million Series A funding. The company said in a press release that this investment will “accelerate SEEN's growth as the premier science-backed, clinically-proven beauty brand, which sits at the inte
- LEO Pharma Set for Five Late-Breaking Presentations at EADVhttps://practicaldermatology.com/news/leo-pharma-set-five-late-breaking-presentations-eadv/2468299/LEO Pharma A/S will present new clinical and real-world data from across its portfolio of products at the 33rd European Academy of Dermatology and Venereology (EADV) Congress from September 25-28 in Amsterdam, Netherlands, the company announced. Five coveted late-breaking presentations wi
- Frontier Acquires Mohs Specialist Doherty Dermatologyhttps://practicaldermatology.com/news/frontier-acquires-mohs-specialist-doherty-dermatology/2468264/Frontier Dermatology announced the acquisition of Doherty Dermatology, a clinic in Bellingham, Washington, that specializes in Mohs micrographic surgery. Doherty Dermatology will be rebranded as Frontier Dermatology (Bellingham South) starting October 1, joining the company's 35 other physician o
- sNDA Accepted for Roflumilast Foam 0.3% for Psoriasishttps://practicaldermatology.com/news/snda-accepted-roflumilast-foam-03-psoriasis/2468261/The US Food and Drug Administration (FDA) has accepted a supplemental new drug application (sNDA) for roflumilast foam 0.3%—a once-daily, next-generation phosphodiesterase-4 (PDE4) inhibitor branded ZORYVE by Arcutis Biotherapeutics, Inc.—for the treatment of adults and adolescents ages 12 and ov
- Delgocitinib for CHE Gains EC Approval, FDA NDA Acceptancehttps://practicaldermatology.com/news/delgocitinib-che-gains-ec-approval-fda-nda-acceptance/2468259/Delgocitinib cream 20 mg/g (2%) reached major milestones in both the United States and Europe, LEO Pharma Inc. announced. The US Food and Drug Administration (FDA) accepted a filing for a New Drug Application (NDA) for LEO Pharma’s AnzupgoÒ for the treatment of adults with moderate-to-seve
- Lebrikizumab Gains FDA Approval for ADhttps://practicaldermatology.com/news/lebrikizumab-gains-fda-approval-ad/2468189/The targeted IL-13 inhibitor lebrikizumab was approved by the US Food and Drug Administration for the treatment of adults and children 12 and older who weigh at least 88 lbs with moderate-to-severe atopic dermatitis that is not well controlled despite treatment with topical prescription therapies
- IGSRT Shows High Recurrence-Free Rates in Non-Melanoma Skin Cancerhttps://practicaldermatology.com/news/igsrt-shows-high-recurrence-free-rates-non-melanoma-skin-cancer/2468185/Nonmelanoma skin cancer (NMSC) treated with Image-Guided Superficial Radiation Therapy (IGSRT) showed consistently high freedom from recurrence rates, regardless of patient age or sex, according to a new analysis. The large retrospective cohort study, published in Geriatrics and c